After additional medical assessments at two more baseline sessions (e.g., brachial artery reactivity, carotid intima media thickness, and small particle lipoprotein testing), participants were randomized to one of six treatment conditions: 1) Bupropion SR (150 mg, bid for 9 weeks total: 1week pre-quit and 8 weeks post-quit); 2) Nicotine Lozenge (2 or 4 mg, based on appropriate dose for dependence level per package instructions, for 12 weeks post-quit); 3) Nicotine Patch (24-hour patch; 21, 14, and 7mg; titrated down over 8 weeks post-quit); 4) Nicotine Patch (24-hour patch; 21, 14, and 7mg; titrated down over 8 weeks post-quit) + Nicotine Lozenge (2 or 4 mg, based on appropriate dose for dependence level per package instructions, for 12 weeks post-quit) combination therapy; 5) Bupropion SR (150 mg, bid for 9 weeks total: 1week pre-quit and 8 weeks post-quit) + Nicotine Lozenge (2 or 4 mg, based on appropriate dose for dependence level per package instructions, for 12 weeks post-quit) combination therapy; or 6) Placebo. It should be noted that “pre-quit” and “post-quit” in this manuscript refer, respectively, to the periods of
